Homozygous Familial Hypercholesterolemia HoFH
Also known as: Homozygous Familial Hypercholesterolaemia (HoFH) / Homozygous Familial Hypercholesterolemia (HoFH) / Familial Hypercholesterolemia - Homozygous / Homozygous Familial Hypercholesterolemia / Familial hypercholesterolemia - homozygous (disorder) / Homozygous familial hypercholesterolaemia / Pure hypercholesterolemia, unspecified / Type IIa hyperlipoproteinemia / Hyperlipoproteinemia Type IIa / Fredrickson Type IIa hyperlipoproteinemia / Fredrickson type IIa hyperlipoproteinemia (disorder) / Type IIa hyperlipoproteinaemia / Fredrickson Type IIa hyperlipoproteinaemia / Fredrickson Type IIa hyperlipidemia / Fredrickson Type IIa hyperlipidaemia / Fredrickson Type IIa lipidemia / Fredrickson Type IIa lipidaemia / Type IIa hyperlipidaemia / Type IIa hyperlipidemia
Drug | Drug Name | Drug Description |
---|---|---|
DB09302 | Alirocumab | A PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C). |
DB00381 | Amlodipine | A calcium channel blocker used to treat hypertension and angina. |
DB01076 | Atorvastatin | An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke. |
DB15354 | Evinacumab | A monoclonal antibody targeted against angiopoetin-like protein 3 (ANGPTL3) used as an adjunct with other lipid-lowering therapies for the treatment of homozygous familiar hypercholesterolemia. |
DB09303 | Evolocumab | A PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. |
DB00973 | Ezetimibe | A cholesterol absorption inhibitor used to lower total cholesterol, LDL-C, Apo-B, and non-HDL-C in primary hyperlipidemia and familial cholesterolemia. |
DB08827 | Lomitapide | A microsomal triglyceride transfer protein inhibitor used to lower cholesterol associated with homozygous familial hypercholesterolemia (HoFH), reducing risk of cardiovascular events such as myocardial infarction and stroke. |
DB05528 | Mipomersen | An oligonucleotide drug used for the treatment of homozygous familial hypercholesterolemia. |
DB01098 | Rosuvastatin | An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke. |
DB00641 | Simvastatin | An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular events including myocardial infarction and stroke. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB18538 | CER-001 | 2 | Completed | 1 |
DB15354 | Evinacumab | 2 | Completed | 1 |
DB00973 | Ezetimibe | 2 | Completed | 1 |
DB14901 | Inclisiran | 2 | Completed | 1 |
DB08827 | Lomitapide | 2 | Completed | 1 |
DB12390 | Seladelpar | 2 | Completed | 1 |
DB09303 | Evolocumab | 2 / 3 | Completed | 1 |
DB16336 | Tafolecimab | 2 / 3 | Completed | 1 |
DB16336 | Tafolecimab | 2 / 3 | Recruiting | 1 |
DB09302 | Alirocumab | 3 | Completed | 1 |
DB06630 | Anacetrapib | 3 | Terminated | 1 |
DB15354 | Evinacumab | 3 | Active Not Recruiting | 1 |
DB15354 | Evinacumab | 3 | Completed | 3 |
DB09303 | Evolocumab | 3 | Completed | 1 |
DB14901 | Inclisiran | 3 | Active Not Recruiting | 1 |
DB14901 | Inclisiran | 3 | Completed | 2 |
DB08827 | Lomitapide | 3 | Active Not Recruiting | 1 |
DB08827 | Lomitapide | 3 | Completed | 2 |
DB08827 | Lomitapide | 3 | Withdrawn | 1 |
DB01098 | Rosuvastatin | 3 | Completed | 2 |
DB09303 | Evolocumab | 4 | Completed | 1 |
DB00973 | Ezetimibe | Not Available | Completed | 1 |
DB08827 | Lomitapide | Not Available | Recruiting | 1 |
DB08827 | Lomitapide | Not Available | Withdrawn | 1 |
DB17639 | RGX-501 | Not Available | Active Not Recruiting | 1 |